HighTower Advisors LLC Has $365,000 Position in Dynavax Technologies Corporation $DVAX

HighTower Advisors LLC trimmed its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 26.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,137 shares of the biopharmaceutical company’s stock after selling 10,085 shares during the quarter. HighTower Advisors LLC’s holdings in Dynavax Technologies were worth $365,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale acquired a new stake in shares of Dynavax Technologies during the first quarter worth $30,000. GF Fund Management CO. LTD. bought a new position in Dynavax Technologies during the fourth quarter worth about $35,000. GAMMA Investing LLC raised its stake in Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 3,627 shares in the last quarter. Moloney Securities Asset Management LLC bought a new stake in Dynavax Technologies in the 1st quarter valued at about $131,000. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in Dynavax Technologies by 31.1% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 13,466 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 3,197 shares during the period. Institutional investors own 96.96% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on DVAX shares. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 target price on shares of Dynavax Technologies in a report on Friday, August 22nd. Wall Street Zen upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $24.33.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $10.12 on Tuesday. The firm has a 50 day moving average of $10.62 and a 200-day moving average of $11.28. Dynavax Technologies Corporation has a 12 month low of $9.22 and a 12 month high of $14.63. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $1.19 billion, a PE ratio of -22.00 and a beta of 1.24.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The business had revenue of $95.44 million for the quarter, compared to analysts’ expectations of $87.55 million. On average, equities research analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Insider Buying and Selling at Dynavax Technologies

In other Dynavax Technologies news, Director Scott Dunseth Myers purchased 3,800 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were bought at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the purchase, the director owned 35,004 shares in the company, valued at approximately $378,743.28. This trade represents a 12.18% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.98% of the company’s stock.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.